CA2292835A1 - Membre ntn-2 de la famille des ligands du facteur de necrose tumorale (tnf) - Google Patents

Membre ntn-2 de la famille des ligands du facteur de necrose tumorale (tnf) Download PDF

Info

Publication number
CA2292835A1
CA2292835A1 CA002292835A CA2292835A CA2292835A1 CA 2292835 A1 CA2292835 A1 CA 2292835A1 CA 002292835 A CA002292835 A CA 002292835A CA 2292835 A CA2292835 A CA 2292835A CA 2292835 A1 CA2292835 A1 CA 2292835A1
Authority
CA
Canada
Prior art keywords
human ntn
human
ntn
polypeptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002292835A
Other languages
English (en)
Inventor
Piotr Masiakowski
David Valenzuela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2292835A1 publication Critical patent/CA2292835A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Abstract

Polypeptides NTN-2 humains et acides nucléiques apparentés. L'invention concerne des polypeptides NTN-2 humains comprenant un domaine de NTN-2 humain ayant une activité spécifique de NTN-2 humain. Ces polypeptides peuvent être produits par des techniques de recombinaison à partir de cellules hôtes transformées avec lesdits acides nucléiques. L'invention concerne en outre des agents de liaison spécifiques et des méthodes pour produire et utiliser les compositions concernées par l'invention.
CA002292835A 1997-06-06 1998-06-03 Membre ntn-2 de la famille des ligands du facteur de necrose tumorale (tnf) Abandoned CA2292835A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4877697P 1997-06-06 1997-06-06
US60/048,776 1997-06-06
US6638797P 1997-11-21 1997-11-21
US60/066,387 1997-11-21
PCT/US1998/011294 WO1998055621A1 (fr) 1997-06-06 1998-06-03 Membre ntn-2 de la famille des ligands du facteur de necrose tumorale (tnf)

Publications (1)

Publication Number Publication Date
CA2292835A1 true CA2292835A1 (fr) 1998-12-10

Family

ID=26726521

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002292899A Abandoned CA2292899A1 (fr) 1997-06-06 1998-06-03 Element ntn-2 de la famille des ligands du tnf
CA002292835A Abandoned CA2292835A1 (fr) 1997-06-06 1998-06-03 Membre ntn-2 de la famille des ligands du facteur de necrose tumorale (tnf)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002292899A Abandoned CA2292899A1 (fr) 1997-06-06 1998-06-03 Element ntn-2 de la famille des ligands du tnf

Country Status (6)

Country Link
EP (1) EP0991759A1 (fr)
JP (1) JP2002517977A (fr)
AU (1) AU7608898A (fr)
CA (2) CA2292899A1 (fr)
IL (1) IL133316A0 (fr)
WO (1) WO1998055621A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
WO1999011791A2 (fr) * 1997-09-05 1999-03-11 University Of Washington Recepteurs et ligands de la famille du facteur de necrose tumorale, acides nucleiques codants et agents de liaison associes
CA2310987A1 (fr) * 1997-11-26 1999-06-03 Eli Lilly And Company Gene de la famille des ligands du tnf
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
WO2000026244A2 (fr) * 1998-11-04 2000-05-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nouveau membre de la famille des facteurs de necrose des tumeurs, ligand du recepteur de la mort cellulaire (drl) et compositions et procedes correspondants
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
SI1642972T1 (sl) * 1999-01-07 2010-05-31 Zymogenetics Inc Terapevtske uporabe BR X topnih receptorjev
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
EE05699B1 (et) 1999-01-25 2014-02-17 Biogen, Inc. BAFF, sellega seonduvad blokeerivad ained ja nende kasutamine B-rakkude ja immunoglobuliinide stimuleerimisel ja p„rssimisel immuunsusreaktsioonides
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
WO2000047740A2 (fr) * 1999-02-12 2000-08-17 Amgen Inc. Proteines associees au facteur de necrose des tumeurs
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
WO2001012812A2 (fr) 1999-08-17 2001-02-22 Biogen, Inc. Recepteur de baff (bcma) et agent immunoregulateur
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001087977A2 (fr) 2000-05-12 2001-11-22 Amgen Inc. Procedes et compositions d'une matiere relative a april/g70, bcma, blys/agp-3, et taci
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
AU6842701A (en) 2000-06-16 2002-01-14 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
ES2387546T3 (es) 2001-05-11 2012-09-25 Amgen Inc. Péptidos y moléculas relacionadas que se unen a TALL-1
DE60234202D1 (de) 2001-05-24 2009-12-10 Zymogenetics Inc Taci-immunoglobulin-fusionsproteine
CA2520097C (fr) 2003-03-28 2014-10-07 Biogen Idec Ma Inc. Recepteurs baff tronques
WO2005051994A2 (fr) * 2003-11-21 2005-06-09 Zymogenetics, Inc. Facteur de necrose tumorale ztnf11
EP1814577B1 (fr) * 2004-10-13 2014-04-23 The Washington University Utilisation de baff dans le traitement du sepsis
ZA200801354B (en) 2005-08-09 2009-08-26 Ares Trading Sa Methods for treating B-cell malignancies using TACI-lg fusion molecule
AR059025A1 (es) 2005-08-09 2008-03-12 Zymogenetics Inc Metodos para el tratamiento y prevencion de proliferacion de celulas anormales utilizando moleculas de fusion taci
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
ES2618543T3 (es) 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
WO2007123765A2 (fr) 2006-03-31 2007-11-01 Human Genome Sciences Inc. NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha
EA015342B1 (ru) 2006-05-15 2011-06-30 Арес Трейдинг С.А. Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
CN106367714A (zh) 2015-07-24 2017-02-01 先健科技(深圳)有限公司 铁基可吸收植入医疗器械与预制管及其制备方法
WO2018115879A1 (fr) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Utilisation d'anticorps anti-sclérostine dans le traitement de l'ostéogenèse imparfaite

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2248823T5 (es) * 1996-10-25 2011-11-03 Human Genome Sciences, Inc. Neutroquina alfa.
AU5705898A (en) * 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents

Also Published As

Publication number Publication date
AU7608898A (en) 1998-12-21
CA2292899A1 (fr) 1998-12-10
EP0991759A1 (fr) 2000-04-12
IL133316A0 (en) 2001-04-30
JP2002517977A (ja) 2002-06-18
WO1998055621A1 (fr) 1998-12-10

Similar Documents

Publication Publication Date Title
AU743490B2 (en) NTN-2 member of TNF ligand family
CA2292835A1 (fr) Membre ntn-2 de la famille des ligands du facteur de necrose tumorale (tnf)
US6475987B1 (en) Tall-1 receptor homologues
BG65519B1 (bg) Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение
KR100620334B1 (ko) 헤르페스 심플렉스 바이러스 유입 매개체에 대한 리간드및 사용 방법
AU9230398A (en) Cysteine rich receptors-train
EP1019502A2 (fr) Nouveau recepteur orphelin
JPH11225774A (ja) 免疫グロブリン遺伝子スーパーファミリーのメンバー、ｐｉｇｒ−１
US20020160451A1 (en) Novel orphan receptors
AU748167B2 (en) Novel nucleic acid and polypeptide
WO1997042321A9 (fr) Proteine transporteuse d'osteoclastes
WO1997042321A1 (fr) Proteine transporteuse d'osteoclastes
WO1999026980A1 (fr) Reactifs et procedes d'utilisation de proteines de la famille sap, nouveaux regulateurs de transduction de signaux
AU753400C (en) Orphan receptors
US6207413B1 (en) Nucleic acids encoding novel orphan cytokine receptors
JPH11215989A (ja) 免疫グロブリン遺伝子スーパーファミリーのメンバー、ｐｉｇｒ−２
JPH1072495A (ja) 免疫関連因子

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20030603